drugset / Trial / NCT01348516

Single Ascending Dose (SAD)/Multiple Ascending Dose(MAD) Safety/Pharmacokinetic (PK) Study of KM-023

NCT01348516

Phase 1 Completed 83 enrolled Kainos Medicine Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to investigate the safety and pharmacokinetics of KM-023 after single/multiple dosing.

Timeline

Start
2011-05
Primary completion
2012-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject KM-023 Unknown 75 mg Oral
Subject KM-023 Unknown 150 mg Oral
Subject KM-023 Unknown 300 mg Oral
Subject KM-023 Unknown 600 mg Oral